Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Medicine and Dentistry

• Protein Expression 100%
• Oncology 100%
• Endometrium Carcinoma 100%
• Gynecological Oncology 100%
• Uterine Cancer 100%
• Messenger RNA 100%
• Neoplasm 66%
• Progression Free Survival 66%
• Primary Tumor 66%
• Biological Marker 33%
• Overall Survival 33%
• Proportional Hazards Model 33%
• Tumor Suppressor Gene 33%
• Adenocarcinoma 33%
• Solid Malignant Neoplasm 33%
• Histone Methyltransferase 33%
• Transcription Factor EZH2 33%
• Western Blot 33%
• Lymph Duct 33%
• Prognostic Factor 33%
• Quantitative Reverse Transcription Polymerase Chain Reaction 33%
• Survival Analysis 33%

Keyphrases

• Overexpression 100%
• Enhancer of Zeste Homolog 2 (EZH2) 100%
• Group Studies 100%
• Gynecologic Oncology Group 100%
• Endometrial Carcinoma 100%
• NRG Oncology 100%
• Protein Expression 25%
• MRNA Expression 16%
• Progression-free Survival 16%
• Primary Tumor 16%
• Endometrial Cancer 16%
• Tumor 8%
• Non-associated 8%
• Overall Survival 8%
• Quantitative PCR 8%
• Pathologic 8%
• Cox Proportional Hazards Model 8%
• Survival Analysis 8%
• Tumor Suppressor Gene 8%
• Solid Tumors 8%
• Tissue Sampling 8%
• Prognostic Factors 8%
• Mullerian 8%
• Advanced Stage 8%
• Expression Level 8%
• Histone Methyltransferase 8%
• Western Blot Analysis 8%
• Clinical Factors 8%
• Lymphovascular Invasion 8%
• Group Communication Protocol 8%
• Patient Samples 8%
• Differential Expression 8%
• Prognostic Biomarker 8%
• Epigenetic Silencing 8%
• Tissue Specimens 8%
• Evaluation Method 8%
• Uterine Cancer 8%
• Tumor Specimens 8%
• Endometrioid Adenocarcinoma 8%
• Pathologic Factors 8%
• Nonparametric Methods 8%